Pranoxen
Pranoxen Brand names, Pranoxen Analogs
Pranoxen Brand Names Mixture
- No information avaliable
Pranoxen Chemical_Formula
C4H6CaO4
Pranoxen RX_link
No information avaliable
Pranoxen fda sheet
Pranoxen msds (material safety sheet)
Pranoxen Synthesis Reference
No information avaliable
Pranoxen Molecular Weight
158.17 g/mol
Pranoxen Melting Point
> 160 oC
Pranoxen H2O Solubility
No information avaliable
Pranoxen State
Solid
Pranoxen LogP
No information avaliable
Pranoxen Dosage Forms
Capsule; Drops; Liquid; Powder for solution; Solution; Tablet
Pranoxen Indication
Used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
Pranoxen Pharmacology
Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Pranoxen Absorption
40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Pranoxen side effects and Toxicity
Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Pranoxen Patient Information
No information avaliable
Pranoxen Organisms Affected
Humans and other mammals
